janneke2024-11-19T13:00:16+01:00 Case study – Target validation by combining Oncolines® profiling and gene dependency screens Case study – Target validation by combining Oncolines® profiling and gene dependency screens Case study – Target validation by combining Oncolines® profiling and gene dependency screens
Oncolines®2024-11-19T13:47:41+01:00 Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™
Oncolines®2024-11-19T13:41:57+01:00 Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin
Oncolines®2024-11-19T13:49:33+01:00 Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors Case study – Stepwise, in-depth cancer gene mutation analysis reveals cellular targeting of KRAS mutant-selective inhibitors
Oncolines®2024-11-19T11:37:24+01:00 Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib
Oncolines®2024-11-19T12:03:15+01:00 Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer
janneke2024-11-19T11:59:34+01:00 Case study – Gene expression profiling to understand and combat drug resistance Case study – Gene expression profiling to understand and combat drug resistance Case study – Gene expression profiling to understand and combat drug resistance
Oncolines®2024-11-19T11:39:02+01:00 Case study – Combination matrix to determine Bliss independence synergy scores Case study – Combination matrix to determine Bliss independence synergy scores Case study – Combination matrix to determine Bliss independence synergy scores
Oncolines®2024-11-19T12:51:07+01:00 Case study – TTK patient stratification marker Case study – TTK patient stratification marker Case study – TTK patient stratification marker
Oncolines®2024-11-19T12:54:57+01:00 Case study – MEK inhibitor Case study – MEK inhibitor Case study – MEK inhibitor
Oncolines®2024-11-19T12:57:31+01:00 Case study – Kadcyla® Case study – Kadcyla® Case study – Kadcyla®
yvonne2024-11-19T13:05:49+01:00 Case study – 3D spheroid drug sensitivity Case study – 3D spheroid drug sensitivity Case study – 3D spheroid drug sensitivity
Oncolines®2024-11-19T13:47:41+01:00 Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™ Case study – Target identification via Oncolines® profiling and ResidenceTimer™
Oncolines®2024-11-19T13:34:48+01:00 Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors
Oncolines®2024-11-19T13:18:25+01:00 Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib
Oncolines®2024-11-19T13:22:41+01:00 Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib Case study – BTK inhibitor fenebrutinib
Oncolines®2024-11-19T13:29:24+01:00 Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors
